多效药片对心血管疾病一级和二级预防的有效性:实用性整群随机对照试验(PolyPars)
PolyPars研究在伊朗南部农村地区开展实用性整群随机对照试验,纳入50-75岁居民4415人,干预组接受每日一次多效药片(含两种降压药、他汀和阿司匹林)加非药物干预,对照组仅非药物干预。中位随访4.6年,多效药片组主要心血管事件风险显著降低(HR 0.50,95%CI 0.38-0.65),绝对风险降低4.0%(95%CI 2.5%-5.3%),严重不良事件无差异。
要点
- 多效药片使主要心血管事件风险减半(HR 0.50,95%CI 0.38-0.65)。
- 绝对风险降低4.0%(95%CI 2.5%-5.3%),干预组依从率86%。
- 严重不良事件两组无差异,支持人群层面安全使用。
核心结论
- 固定剂量组合多效药片可安全地将人群主要心血管疾病风险减半。
研究设计与样本
- 实用性整群随机对照试验,嵌套于PARS队列研究,覆盖伊朗南部农村全部50岁以上居民。
- 91个村庄随机分为两组:对照组45个集群接受非药物干预(健康教育),干预组46个集群接受非药物干预加每日一次多效药片。
- 多效药片含两种降压药、一种他汀和阿司匹林。
- 共纳入4415名50-75岁参与者(干预组2200人,对照组2215人),中位随访4.6年(四分位间距4.4-4.9)。
主要发现
- 干预组多效药片依从率为86%。
- 对照组2215人中176人(8.0%)发生主要结局,多效药片组2200人中88人(4.0%)发生主要结局。
- 主要结局风险显著降低:HR 0.50(95%CI 0.38-0.65),绝对风险降低4.0%(95%CI 2.5%-5.3%)。
- 两组严重不良事件无差异。
关键数值与推荐
- 主要结局定义为主要心血管事件首次发生,包括因急性冠脉综合征住院(非致死性心肌梗死和不稳定型心绞痛)、致死性心肌梗死、非致死性和致死性卒中、猝死及心力衰竭。
临床怎么用
- 在资源有限的农村人群中,每日一次多效药片可作为心血管疾病一级和二级预防的有效策略。
- 多效药片使用需基于人群层面推广,并配合健康生活方式教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to investigate the effectiveness of fixed-dose combination therapy (polypill) for primary and secondary prevention of major cardiovascular diseases in a typical rural setting. METHODS: The PolyPars Study is a two-arm pragmatic cluster-randomised trial nested within the PARS cohort study, including all residents aged over 50 years in the entire district in southern Iran. The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet. This tablet comprised two antihypertensive agents, a statin and aspirin. The primary outcome was the first occurrence of major cardiovascular events defined as a composite of hospitalisation for acute coronary syndrome (non-fatal myocardial infarction and unstable angina), fatal myocardial infarction, non-fatal and fatal stroke, sudden death and heart failure. The Cox regression model, with shared frailty, was used to account for clustering effect. RESULTS: During December 2015-December 2016, a total of 4415 participants aged 50-75 years were recruited (2200 participants in the intervention arm and 2215 participants in the control arm). The overall median of follow-up duration was 4.6 years (interquartile interval 4.4-4.9). The achieved adherence rate to polypill in intervention arm was 86%. In the control group, 176 (8.0%) of 2215 participants developed primary outcome, compared with 88 (4.0%) of 2200 participants in the polypill group. We found substantial reduction in risk of primary outcome both in relative and absolute scales (HR 0.50, 95% CI 0.38 to 0.65; absolute risk reduction 4.0%, 95% CI 2.5% to 5.3%). No difference in serious adverse events was observed between the two groups. CONCLUSIONS: The fixed-dose combination therapy using polypill can safely halve the risk of major cardiovascular diseases at the population level. TRIAL REGISTRATION NUMBER: NCT03459560.
引用
- Malekzadeh, Gandomkar, Poustchi, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars). Heart. 2024. PMID: 38485210. doi:10.1136/heartjnl-2023-323614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。